In another combination study, the resistance in melanoma patients following the use of the Hsp90 inhibitor XL888 with the BRAF inhibitor vemurafenib was reverted by the use of dinaciclib as a CDK2 inhibitor [22]. The gene discussed is CDK2; the disease is melanoma.